1. HBW Insight
  2. >>Archive

Hi-Tech Tangles With FDA Again: Plans Litigation To Keep DMHA Available

 
• By Malcolm Spicer

Hi-Tech Pharmaceuticals says it will "continue to supply its customers with DMHA-containing products until there is a final, judicial determination." Firm, currently appealing a ruling upholding a previous FDA action, says DMHA "is a stimulant compound naturally found in Walnut Bark extract" and walnuts "are the oldest tree food known to man."

One of the eight firms the US Food and Drug Administration recently warned about dietary supplements with an ingredient the agency has concluded is violative, DMHA, doesn't agree and isn't planning to cease marketing the product.

Hi-Tech Pharmaceuticals Inc. on April 17 announced it will "continue to supply its customers with DMHA-containing products until there is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from HBW Insight

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

Health and Human Services secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Lupin Goes For Growth With Indian Consumer Health Spin-Off

 
• By Tom Gallen

With annual sales approaching $20m, LupinLife Consumer Healthcare has ambitious growth plans for the Indian OTC market.